FDA Approves New MS Drug - FoxNews.com

Links shared publicly online about this topic.

  • 854
    total visits

FDA Approves New MS Drug - FoxNews.com

foxnews.com

Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.

View full resource at foxnews.com

Tags: Nervous System, Multiple Sclerosis, Multiple Sclerosis Medication, Drug, Healthy Living, FDA

  • Share

Most Recently Shared on September 22, 2010 at 10:49 pm By:

Report: FDA strengthens monitoring of post-approval drug safety

fda.gov — “A strengthened and modernized postmarket drug safety program has resulted in a substantial improvement in the U.S. Food and Drug Administration’s oversight of drugs once they reach the American public, according to a new report released today by the agency’s Center for Drug Evaluation and Research (CDER). The report, “Advances in FDA’s Safety Program for Marketed Drugs,” describes new scientific tools and enhanced capabilities that give the same priority to postmarket drug safety monitoring as tView full resource at fda.gov

  • View Related
  • Share

Most Recently Shared on April 21, 2012 at 8:42 pm By:

HealthTrendster HealthTrendster Health Executive

Report: FDA strengthens monitoring of post-approval drug safety: A strengthened and… http://t.co/Nlax6RLR

3 days ago...

New diet drug Qnexa awaits FDA approval amid safety questions – USATODAY.com

usatoday.com — “Some experts say it could potentially help dieters lose about 10% of their weight, but with its former FDA rejection, how safe is it?View full resource at usatoday.com

  • View Related
  • Share

Most Recently Shared on April 4, 2012 at 10:45 pm By:

USATODAYhealth Maureen Linke Health News

Diet drug Qnexa awaits FDA approval amid safety questions http://t.co/YjlUT7Bn

3 weeks ago...

FDA Finds New Batch of Fake Avastin - WSJ.com

online.wsj.com — “The Food and Drug Administration has found a new batch of counterfeit Avastin circulating in the U.S. and apparently distributed by a different network from the one connected to an earlier fake supply of the cancer drug. The new fakes were packaged in boxes labeled as Altuzan, the brand name for Avastin in Turkey, the FDA said.View full resource at online.wsj.com

  • View Related
  • Share

Most Recently Shared on April 4, 2012 at 6:12 am By:

Consumer Reports Warns of Lax Testing for Medical Devices - ABC News

abcnews.go.com — “Consumer Reports advises patients to do their homework before having medical devices implanted in their bodies.  Companies that sell defibrillators, stents or other such products can get approval from the Food and Drug Administration without their undergoing rigorous testing, Consumer Reports warned in a new report. The FDA collects information on medical device malfunctions that lead to death. Data highlighted by Consumer Reports show 686 deaths from 2009 to last year connected to automateView full resource at abcnews.go.com

  • View Related
  • Share

Most Recently Shared on March 29, 2012 at 7:39 pm By:

HITpol HealthIT Policy Health IT and Health News

Consumer Reports Warns of Lax Testing for Medical Devices: Consumer Reports advises patients to do their homewor... http://t.co/z5sM68RZ

4 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 28, 2012 at 6:19 pm By:

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 28, 2012 at 1:16 am By:

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 7:30 pm By:

HealthTrendster HealthTrendster Health Executive

F.D.A. Approves New Anemia Drug - A new anemia drug provides a less expensive alternative for dialysis patients and ... http://t.co/9YfRzcyE

4 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The F.D.A. approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 7:15 pm By:

Health_CK Catherine K Health Advocate

F.D.A. Approves New Anemia Drug: A new anemia drug provides a less expensive alternative for dialysis patients a... http://t.co/4Ku4AF4F

4 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 6:27 pm By:

DrAnasYounes Anas Younes, M.D. Doctor, Internist, Oncologist, and Physician

F.D.A. Approves Affymax's new drug Omontys for anemic patients receiving kidney dialysis... http://t.co/2o68syVQ

4 weeks ago...

Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com

nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.View full resource at nytimes.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 6:21 pm By:

Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Xconomy

xconomy.com — “Affymax completed its surprising comeback today, as it won FDA clearance for its first marketed drug, a product for anemia that will be the first to rival aView full resource at xconomy.com

  • View Related
  • Share

Most Recently Shared on March 27, 2012 at 4:58 pm By:

ldtimmerman Luke Timmerman Health Communicator

Update to Affymax FDA approval story, with comments from CEO John Orwin. Conf call coming later today. http://t.co/bG1ow9T0

4 weeks ago...

FDA approves Teva's QNASL nasal aerosol corticosteroid

news-medical.net — “Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on March 26, 2012 at 7:03 pm By:

asthma_news News-Medical.Net Health News

Asthma News: FDA approves Teva's QNASL nasal aerosol corticosteroid: Teva Pharmaceutical Industries Ltd. announc... http://t.co/2cZSMyF6

4 weeks ago...

FDA ponders need for heart studies ahead of drug approvals; New VC fund takes shape for Scotland; - FierceBiotech

fiercebiotech.com — “@FierceBiotech: Amgen's AMG 145 cuts cholesterol by 66% in early-stage trial involving patients taking statins. Article | Follow @FierceBiotech @JohnCFierce: Merck: I paid $41 billion for Read more...View full resource at fiercebiotech.com

  • View Related
  • Share

Most Recently Shared on March 26, 2012 at 4:57 pm By:

carybyrd Cary Byrd - eDrugSearch.com Pharma and Health Advocate

FDA ponders need for heart studies ahead of drug approvals; New VC fund takes shape for Scotland; - FierceBiotech http://t.co/bpFa4yK5

4 weeks ago...

Experts challenge FDA over approval for new dose of Alzheimer's drug | Science Codex

sciencecodex.com — “Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts on bmj.com today. In the first of a new occasionalView full resource at sciencecodex.com

  • View Related
  • Share

Most Recently Shared on March 23, 2012 at 11:58 am By:

sarasteinmd Sara Stein MD Physician, Doctor, and Psychiatrist

#Dementia Pharma at its worst again, distorted advertising on Aricept to get you buying the new name brand version... http://t.co/puM4CgEj

1 month ago...

Experts challenge FDA over approval for new dose of Alzheimer?s drug

alzheimersreadingroom.com — “Experts challenge FDA over approval for new dose of Alzheimer?s drugView full resource at alzheimersreadingroom.com

  • View Related
  • Share

Most Recently Shared on March 23, 2012 at 2:55 am By:

ALZHEIMERSreadAlzheimer's Reading Room is the number one source of life news for the entire Alzheimer's community. Our goal is to Educate, sometimes Entertain, and Empower Alzheimers caregivers and their families worldwide.


" /> Alzheimer's Reading Room Health Advocate

http://t.co/cd0mwZ54 http://t.co/8NsUVoCU

1 month ago...

Advertisement